Details of the Drug

General Information of Drug (ID: DM08E9O)

Drug Name

Diazepam

Synonyms

diazepam; Valium; 439-14-5; Diazemuls; Ansiolisina; Sibazon; Relanium; Faustan; Apaurin; Stesolid; Seduxen; Methyldiazepinone; Valitran; Tranqdyn; Seduksen; Relaminal; Quiatril; Quetinil; Dipezona; Diazetard; Diazepan; Calmpose; Tranimul; Tensopam; Serenack; Paranten; Kiatrium; Domalium; Condition; Bialzepam; Ansiolin; Unisedil; Stesolin; Serenamin; Ruhsitus; Renborin; Quievita; Tranquirit; Serenzin; Neurolytril; Liberetas; Diacepan; Ceregulart; Calmocitene; Bensedin; Atensine; Apozepam; Umbrium; Sonacon; Sedipam; Levium; Diapam; Atilen; Assival; Amiprol; Diazepam (intranasal, epilepsy)

Indication

Disease Entry	ICD 11	Status	REF
Alcohol withdrawal	N.A.	Approved	[1]
Alcohol withdrawal delirium	N.A.	Approved	[1]
Anxiety	N.A.	Approved	[1]
Epilepsy	8A60-8A68	Approved	[2]
Tetanus	1C13	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

284.74

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.38 mL/min/kg [5]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 42 hours [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.00784 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.023% [5]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1 L/kg [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.057 mg/mL [3]

Adverse Drug Reaction (ADR)

ADR Term	Variation	Related DOT	DOT ID	REF
Sedation	Not Available	TSPO	OTSU7ESK	[7]
-----------

Chemical Identifiers

Formula: C16H13ClN2O
IUPAC Name: 7-chloro-1-methyl-5-phenyl-3H-1,4-benzodiazepin-2-one
Canonical SMILES: CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3
InChI: InChI=1S/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3
InChIKey: AAOVKJBEBIDNHE-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3016
ChEBI ID: CHEBI:49575
CAS Number: 439-14-5
DrugBank ID: DB00829
TTD ID: D07JVL
VARIDT ID: DR00999
INTEDE ID: DR0480
ACDINA ID: D00190

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Agonist	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[11]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[12]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[13]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[14]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[15]
Cytochrome P450 2C8 (CYP2C8)	DES5XRU	CP2C8_HUMAN	Substrate	[16]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[17]
Prostaglandin G/H synthase 1 (COX-1)	DE073H6	PGH1_HUMAN	Substrate	[18]
Cytochrome P450 2C18 (CYP2C18)	DEZMWRE	CP2CI_HUMAN	Substrate	[19]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Protein Interaction/Cellular Processes	[20]
Aldo-keto reductase family 1 member C1 (AKR1C1)	OTQKR4CM	AK1C1_HUMAN	Gene/Protein Processing	[21]
Aldo-keto reductase family 1 member C2 (AKR1C2)	OTQ2XMO3	AK1C2_HUMAN	Gene/Protein Processing	[21]
Aldo-keto reductase family 1 member C3 (AKR1C3)	OTU2SXBA	AK1C3_HUMAN	Gene/Protein Processing	[21]
Aldo-keto reductase family 1 member C4 (AKR1C4)	OTW2MMOF	AK1C4_HUMAN	Gene/Protein Processing	[21]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[22]
Biglycan (BGN)	OT3AV6IF	PGS1_HUMAN	Gene/Protein Processing	[23]
Collagen alpha-1(I) chain (COL1A1)	OTI31178	CO1A1_HUMAN	Gene/Protein Processing	[23]
Collagen alpha-1(VII) chain (COL7A1)	OT3MIRZJ	CO7A1_HUMAN	Gene/Protein Processing	[23]
Fibroblast growth factor 2 (FGF2)	OT7YUJ9F	FGF2_HUMAN	Gene/Protein Processing	[23]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Alcohol withdrawal

ICD Disease Classification

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Translocator protein (TSPO)	DTT	TSPO	2.65E-05	1.98	4.26
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.45E-02	-1.49E-01	-3.47E-01
Cytochrome P450 2C18 (CYP2C18)	DME	CYP2C18	7.46E-02	-1.26E-01	-3.29E-01
Cytochrome P450 2C8 (CYP2C8)	DME	CYP2C8	7.62E-02	-1.65E-01	-6.38E-01
Cytochrome P450 2B6 (CYP2B6)	DME	CYP2B6	7.53E-01	1.26E-01	4.92E-01
Cytochrome P450 1A2 (CYP1A2)	DME	CYP1A2	7.68E-02	-2.10E-01	-6.42E-01
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	1.34E-01	-2.79E-01	-7.05E-01
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	5.48E-01	1.12E-01	7.24E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	4.28E-02	-1.99E-01	-6.09E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.81E-01	2.72E-01	6.95E-01
Prostaglandin G/H synthase 1 (COX-1)	DME	PTGS1	7.25E-01	-4.31E-02	-5.74E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Diazepam

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Diazepam caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[24]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Diazepam caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[25]
-----------

Coadministration of a Drug Treating the Disease Different from Diazepam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Altered absorption of Diazepam due to GI dynamics variation caused by Sodium bicarbonate.	Acidosis [5C73]	[26]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Diazepam and Oliceridine.	Acute pain [MG31]	[27]
Emapalumab	DMZG5WL	Moderate	Altered metabolism of Diazepam due to Emapalumab alters the formation of CYP450 enzymes.	Adaptive immunity immunodeficiency [4A01]	[28]
Siltuximab	DMGEATB	Moderate	Altered metabolism of Diazepam due to Siltuximab alters the formation of CYP450 enzymes.	Anemia [3A00-3A9Z]	[28]
Dronedarone	DMA8FS5	Moderate	Decreased clearance of Diazepam due to the transporter inhibition by Dronedarone.	Angina pectoris [BA40]	[29]
Posaconazole	DMUL5EW	Moderate	Decreased metabolism of Diazepam caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[30]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Diazepam caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[31]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Diazepam caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Troleandomycin	DMUZNIG	Moderate	Decreased metabolism of Diazepam caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[32]
Lapatinib	DM3BH1Y	Moderate	Decreased clearance of Diazepam due to the transporter inhibition by Lapatinib.	Breast cancer [2C60-2C6Y]	[33]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Diazepam caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Diazepam and Dihydrocodeine.	Chronic pain [MG30]	[35]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Diazepam and Remifentanil.	Corneal disease [9A76-9A78]	[27]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Diazepam caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[36]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Diazepam due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[37]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Diazepam and Ethanol.	Cystitis [GC00]	[38]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Diazepam caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[39]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Diazepam and Esketamine.	Depression [6A70-6A7Z]	[36]
SODIUM CITRATE	DMHPD2Y	Minor	Altered absorption of Diazepam due to GI dynamics variation caused by SODIUM CITRATE.	Discovery agent [N.A.]	[26]
Itraconazole	DMCR1MV	Moderate	Decreased metabolism of Diazepam caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[30]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Diazepam caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[30]
Ketoconazole	DMPZI3Q	Moderate	Decreased metabolism of Diazepam caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[30]
Bumetanide	DMRV7H0	Moderate	Additive hypotensive effects by the combination of Diazepam and Bumetanide.	Heart failure [BD10-BD1Z]	[40]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Diazepam caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[41]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Diazepam caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[42]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Diazepam caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[43]
Rifampin	DMA8J1G	Minor	Increased metabolism of Diazepam caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[44]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Diazepam caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[45]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Diazepam caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Cobicistat	DM6L4H2	Moderate	Decreased clearance of Diazepam due to the transporter inhibition by Cobicistat.	Human immunodeficiency virus disease [1C60-1C62]	[47]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Diazepam caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[48]
Didanosine	DMI2QPE	Minor	Altered absorption of Diazepam due to GI dynamics variation caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[26]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Diazepam caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[49]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Diazepam caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[50]
Probenecid	DMMFWOJ	Minor	Decreased metabolism of Diazepam caused by Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[51]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Diazepam caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[52]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Diazepam caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[53]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Diazepam caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[36]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Diazepam caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[54]
Vemurafenib	DM62UG5	Moderate	Decreased metabolism of Diazepam caused by Vemurafenib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[36]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Diazepam caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[28]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Diazepam and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[55]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Diazepam and Lasmiditan.	Migraine [8A80]	[56]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Diazepam caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[57]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Diazepam and Flibanserin.	Mood disorder [6A60-6E23]	[58]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Diazepam and Thalidomide.	Multiple myeloma [2A83]	[59]
Teduglutide	DMYOAKS	Moderate	Altered absorption of Diazepam caused by Teduglutide.	Neonatal malabsorption syndrome [KB89]	[60]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Diazepam and Levomethadyl Acetate.	Opioid use disorder [6C43]	[35]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Diazepam and Apraclonidine.	Optic nerve disorder [9C40]	[61]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Diazepam caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[62]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Diazepam and Oxymorphone.	Pain [MG30-MG3Z]	[27]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Diazepam and Levorphanol.	Pain [MG30-MG3Z]	[27]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Diazepam and Dezocine.	Pain [MG30-MG3Z]	[27]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Diazepam and Nalbuphine.	Pain [MG30-MG3Z]	[27]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Diazepam and Buprenorphine.	Pain [MG30-MG3Z]	[63]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Diazepam and Hydrocodone.	Pain [MG30-MG3Z]	[27]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Diazepam caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[64]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Diazepam caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[65]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Diazepam caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[66]
Ustekinumab	DMHTYK3	Moderate	Altered metabolism of Diazepam due to Ustekinumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[28]
Ixekizumab	DMXW92T	Moderate	Altered metabolism of Diazepam due to Ixekizumab alters the formation of CYP450 enzymes.	Psoriasis [EA90]	[28]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Diazepam and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[67]
Tocilizumab	DM7J6OR	Moderate	Altered metabolism of Diazepam due to Tocilizumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Canakinumab	DM8HLO5	Moderate	Altered metabolism of Diazepam due to Canakinumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Rilonacept	DMGLUQS	Moderate	Altered metabolism of Diazepam due to Rilonacept alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Sarilumab	DMOGNXY	Moderate	Altered metabolism of Diazepam due to Sarilumab alters the formation of CYP450 enzymes.	Rheumatoid arthritis [FA20]	[28]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Diazepam caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[36]
LEE011	DMMX75K	Moderate	Decreased metabolism of Diazepam caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[68]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Diazepam due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[69]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Diazepam and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[67]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Diazepam and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[67]
Amiodarone	DMUTEX3	Minor	Potentiate the pharmacologic effects by the combination of Diazepam and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[70]
-----------


⏷ Show the Full List of 72 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 1	E00263	19700	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Calcium stearate	E00244	15324	lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Galactose	E00093	6036	Complexing agent; Flavoring agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Diazepam 10 mg tablet	10 mg	Oral Tablet	Oral
Diazepam 5 mg tablet	5 mg	Oral Tablet	Oral
Diazepam 2 mg tablet	2 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Diazepam FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3364).
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8	Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
9	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
10	Comparative study of the metabolism of drug substrates by human cytochrome P450 3A4 expressed in bacterial, yeast and human lymphoblastoid cells. Xenobiotica. 2002 Nov;32(11):937-47.
11	Phenytoin-diazepam interaction. Ann Pharmacother. 2003 May;37(5):659-63.
12	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
13	In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact. 2003 Dec 15;146(3):263-72.
14	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
15	Inhibitory monoclonal antibody to human cytochrome P450 2B6. Biochem Pharmacol. 1998 May 15;55(10):1633-40.
16	Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism. Eur J Pharmacol. 2000 Apr 14;394(2-3):199-209.
17	Drug Interactions Flockhart Table
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
20	The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
21	Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
22	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
23	Patterns of some extracellular matrix gene expression are similar in cells from cleft lip-palate patients and in human palatal fibroblasts exposed to diazepam in culture. Toxicology. 2009 Mar 4;257(1-2):10-6. doi: 10.1016/j.tox.2008.12.002. Epub 2008 Dec 9.
24	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
25	Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
26	Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
27	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
28	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
30	Ahonen J, Olkkola KT, Neuvonen PJ "The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam." Fundam Clin Pharmacol 10 (1996): 314-8. [PMID: 8836707]
31	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
32	Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17. [PMID: 8547740]
33	Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
34	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
35	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
36	Cerner Multum, Inc. "Australian Product Information.".
37	Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
38	Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
39	Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
40	Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595. [PMID: 9518913]
41	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
42	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
43	Ochs HR, Greenblatt DJ, Knuchel M "Differential effect of isoniazid on triazolam oxidation and oxazepam conjugation." Br J Clin Pharmacol 16 (1983): 743-6. [PMID: 6140941]
44	Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
45	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
46	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
47	Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
48	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
49	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
50	Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
51	Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
52	Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
53	Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
54	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
55	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
56	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
57	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
58	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
59	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
60	Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
61	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
62	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
63	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
64	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
65	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
66	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
67	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
68	DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
69	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
70	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]